81289 Fxn gene known famil variant
Also known as: FXN familial variant analysis, FXN family screening
Frataxin (FXN) gene analysis for known familial variants to facilitate targeted testing in family members with suspected Friedreich's ataxia.
In Plain Language
Familial ataxia genetic test; Family member ataxia screening
Clinical Context
Tests family members for known FXN variants identified in affected relatives. Improves diagnostic accuracy and enables early intervention planning.
RVU Information
CPT 81289 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 81289?
CPT 81289 (Fxn gene known famil variant) is a Pathology & Lab code. Frataxin (FXN) gene analysis for known familial variants to facilitate targeted testing in family members with suspected Friedreich's ataxia.
Who uses CPT code 81289?
CPT 81289 is used by Pathology, Neurology, Genetics. Tests family members for known FXN variants identified in affected relatives. Improves diagnostic accuracy and enables early intervention planning.
When is CPT 81289 used?
Tests family members for known FXN variants identified in affected relatives. Improves diagnostic accuracy and enables early intervention planning.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.